Kiniksa’s Vixarelimab Receives the US FDA’s Breakthrough Therapy Designation to Treat Pruritus Associated with Prurigo Nodularis

 Kiniksa’s Vixarelimab Receives the US FDA’s Breakthrough Therapy Designation to Treat Pruritus Associated with Prurigo Nodularis

Kiniksa’s Vixarelimab Receives the US FDA’s Breakthrough Therapy Designation to Treat Pruritus Associated with Prurigo Nodularis

Shots:

  • The BTD is based on P-IIa assessing vixarelimab in reducing pruritus in patients with prurigo nodularis
  • The study met its 1EPs i.e reduction in WI-NRS from baseline @8wks. in vixarelimab recipients and patients also received PN-IGA score of 0/1 @8wks.
  • Kiniksa expects to initiate a P-IIb clinical trial of vixarelimab in prurigo nodularis, evaluating a range of once-monthly dose regimens, by the end of 2021. Vixarelimab is a fully-human mAb that targets oncostatin M receptor beta (OSMRβ)

Click here ­to­ read full press release/ article | Ref: GlobeNewswire | Image: Kiniksa

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post